# Better Acceptance of Single Injection Apidra Added to Once Daily Lantus Versus Twice Daily Premixed Insulin in Real Life Use Setting

> **NCT01079364** · PHASE4 · TERMINATED · sponsor: **Sanofi** · enrollment: 52 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Insulin glulisine
- **DRUG:** Insulin glargine
- **DRUG:** Premixed insulin (Insulin Aspart 30/70 )

## Key facts

- **NCT ID:** NCT01079364
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-01
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 52 (ACTUAL)
- **Why stopped:** Slow recruitment
- **Last updated:** 2013-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01079364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01079364, "Better Acceptance of Single Injection Apidra Added to Once Daily Lantus Versus Twice Daily Premixed Insulin in Real Life Use Setting". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01079364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*